Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03689699
Recruitment Status : Active, not recruiting
First Posted : September 28, 2018
Last Update Posted : May 11, 2022
Sponsor:
Collaborator:
Bristol-Myers Squibb
Information provided by (Responsible Party):
Matthew Dallos, Columbia University

Brief Summary:

MAGIC-8 is a two-arm, multicenter, phase 1b/2 study to assess the efficacy of immunotherapy with either Nivolumab (anti-PD-1) or Nivolumab plus BMS-986253 combined with ADT using Degarelix (LHRH antagonist) for men with hormone-sensitive prostate cancer and a rising prostate-sepcific antigen (PSA). The purpose of this study is to see whether immunotherapy with either Nivolumab alone or Nivolumab plus BMS-986253 combined with Degarelix, which suppresses testosterone, is safe and can decrease the chance that the cancer will come back.

The primary objectives are to 1) determine the rate of PSA recurrence defined as a PSA >0.2ng/ml for radical prostatectomy patients or PSA >2.0ng/ml for patients who received primary radiation therapy at a time point of 10 months after start of therapy; and 2) determine the safety and tolerability of either nivolumab or nivolumab plus BMS-986253 in combination with degarelix in men with hormone-sensitive prostate cancer. The secondary objectives include determining relapse-free survival (RFS) and % change in PSA to immunotherapy alone.


Condition or disease Intervention/treatment Phase
Prostate Cancer Adenocarcinoma of the Prostate Drug: Nivolumab Drug: Degarelix Drug: BMS-986253 Phase 1 Phase 2

Detailed Description:

Prostate cancer is common and remains a major cause of death in men. Following local therapy with surgery or radiation, a significant number of men recur either with a rising PSA only (biochemical recurrence (BCR)) or clear metastatic disease on imaging. Although androgen deprivation therapy (ADT) is a frequently used and effective treatment for prostate cancer, it is associated with significant side effects including fatigue, hot flashes, decreased libido and bone loss. Therefore, new approaches to decrease the time on ADT are crucial to improving quality of life for men with prostate cancer.

Once initiated, ADT can be given either continuously or intermittently. However, even with an intermittent approach the ADT-free interval typically decreases with each cycle and most men eventually develop castration resistance. Therefore new treatment strategies are needed to improve disease control while minimizing ADT exposure for men with early prostate cancer.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: The study will include a total of approximately 30 patients per arm to achieve at least 23 evaluable patients per arm.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Randomized Phase 1b/2 Study of Nivolumab or Nivolumab Plus BMS-986253 in Combination With Intermittent Androgen Deprivation Therapy in Men With Hormone-Sensitive Prostate Cancer
Actual Study Start Date : October 11, 2018
Estimated Primary Completion Date : January 2023
Estimated Study Completion Date : August 2023

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Arm A: Nivolumab alone
Men with hormone-sensitive prostate cancer will receive Nivolumab alone every 4 weeks for 8 weeks (2 doses), followed by Nivolumab + Degarelix every 4 weeks for 16 weeks (4 doses).
Drug: Nivolumab
A dose of 480mg every 4 weeks as a 30 minute IV infusion for 6 doses has been selected for this study. 6 total doses.
Other Name: Opdivo®

Drug: Degarelix
Standard treatment at a dose of 240mg subcutaneously (SQ) as a loading dose followed by 80mg SQ every 4 weeks for 4 doses.
Other Name: Firmagon®

Experimental: Arm B: Nivolumab plus BMS-986253
Men with hormone-sensitive prostate cancer will receive Nivolumab plus BMS-986253 every 4 weeks for 8 weeks (2 doses), followed by Nivolumab + BMS-986253 + Degarelix every 4 weeks for 16 weeks (4 doses).
Drug: Nivolumab
A dose of 480mg every 4 weeks as a 30 minute IV infusion for 6 doses has been selected for this study. 6 total doses.
Other Name: Opdivo®

Drug: Degarelix
Standard treatment at a dose of 240mg subcutaneously (SQ) as a loading dose followed by 80mg SQ every 4 weeks for 4 doses.
Other Name: Firmagon®

Drug: BMS-986253
BMS-986253 (also referred to as anti-IL8 mAb or HuMax IL8) is a fully human-sequence IgG1κ monoclonal antibody (mAb) directed against human interleukin-8 (IL-8). Subjects will be treated with an intravenous (IV) flat dose of 2400mg every 2 weeks.
Other Name: HuMax IL-8




Primary Outcome Measures :
  1. Rate of PSA recurrence [ Time Frame: Up to 10 months after completion of therapy ]
    Defined as a PSA >0.2ng/ml for radical prostatectomy patients or PSA >2.0ng/ml for patients who received primary radiation therapy at a time point of 10 months after start of therapy.

  2. Determine Safety and Tolerability [ Time Frame: Up to two years ]
    Adverse events that are serious in nature and related to the investigational product will be recorded.


Secondary Outcome Measures :
  1. Percentage change in PSA [ Time Frame: Baseline, 8 weeks ]
    Determine the % change in PSA in response to immunotherapy by comparing the PSA prior to and following 8 weeks of immunotherapy and before initiation of ADT

  2. Relapse-free survival (RFS) [ Time Frame: Up to two years ]
    Relapse defined as a PSA >0.2ng/ml for radical prostatectomy patients or PSA >2.0ng/ml for patients who received primary radiation therapy.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 99 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically documented prostatic adenocarcinoma confirmed by a pathology report from prostate biopsy or a radical prostatectomy specimen.
  • Age ≥18 years
  • Previously undergone primary therapy for prostate cancer. Salvage XRT or cryotherapy following primary therapy ≥ 6 months prior to randomization is allowed.
  • A rising PSA defined as the following:

    • If the subject's primary therapy was RP (with or without adjuvant or salvage XRT), rising PSA is defined as 2 consecutive rising values above 0.2 ng/mL, each taken ≥ 3 weeks apart, and the last value ≥ 2.0 ng/mL
    • If the subject received other primary therapies (e.g. XRT, cryosurgery, brachytherapy), rising PSA is defined per the Phoenix definition, i.e., 2 consecutive rising values above the PSA nadir plus 2.0 ng/mL.
  • For the biopsy sub-groups, patients must be willing to undergo pre and on- treatment biopsies.
  • PSADT ≤ 12 months. PSADT will be determined from all non-zero PSA values collected preferably, however not limited to, from the 12 months prior to randomization. To calculate PSADT, there must be at least THREE PSA values, with at least 4 weeks between each measurement. The PSADT will be computed from the formula: PSADT = (loge2)/k, with k being the estimated slope of the logarithm of PSA over time. The following web site may also be used: http://www.mskcc.org/applications/nomograms/prostate/PsaDoublingTime.aspx
  • ECOG performance status 0-1, or Karnofsky score ≥ 70% (see Appendix A)
  • Testosterone ≥ 150 ng/dL ≤ 28 days of prior to registration
  • Adequate bone marrow, hepatic, and renal function:

    • WBC >3,000 cells/mm3
    • ANC >1,500 cells/mm3
    • Hemoglobin >9.0 g/dL
    • Platelet count >100,000 cells/mm3
    • Serum creatinine <1.5 × upper limit of normal (ULN)
    • Serum total bilirubin <1.5 × ULN
    • ALT <3 × ULN
    • AST <3 × ULN
  • Willingness to provide written informed consent and HIPAA authorization for the release of personal health information, and the ability to comply with the study requirements (note: HIPAA authorization will be included in the informed consent)
  • Willingness to use barrier contraception during treatment plus 5 half-lives of niovlumab (~125 days) plus 90 days (duration of sperm turnover) for a total of 215 days post-treatment completion (azospermic men are not exempt from contraceptive requirements)

Exclusion Criteria:

Received any experimental immunotherapy on an experimental clinical trial ≤ 1 year prior to randomization

  • PSA > 50 at time of enrollment
  • High volume disease defined as >5 bone metastases or lymph nodes >3cm in size.
  • Histologic predominance of other types of prostate cancers such as sarcomatous, lymphoma, small cell, and neuroendocrine tumors (note: a maximum of 5 subjects with ductal prostate cancer will be allowed to enroll to each arm of study treatment across all sites).
  • Received salvage XRT ≤ 6 months prior to randomization
  • Received ADT ≤ 6 months prior to randomization
  • Received any form of chemotherapy ≤ 90 days prior to randomization
  • Received granulocyte colony-stimulating factor or GM-CSF ≤ 90 days prior to randomization
  • Any major surgery requiring general anesthesia ≤ 28 days prior to randomization.
  • Any other concurrent or prior treatment for prostate cancer ≤ 28 days prior to randomization.
  • An active infection requiring parenteral antibiotic therapy or causing fever (temperature > 100.5 o F or 38.1 o C) within 1 week prior to randomization
  • Prior systemic, ongoing immunosuppressive therapy ≤ 14 days prior to study treatment administration (except for adrenal replacement steroid doses ≤ 10mgdaily prednisone equivalent in the absence of active autoimmune disease or a short course of steroids (<5 days) up to 7 days prior to initiating study treatment).
  • Prior participation in an anti-IL8 clinical study
  • A candidate is scheduled or likely to be scheduled for salvage external beam XRT or surgery for prostate cancer during the study period
  • Concomitant treatment with other hormonal therapy or 5α-reductase inhibitors such as Dutasteride or Finasteride (prior use of these agents is allowed if ≥3 months prior to randomization).
  • History of known or suspected autoimmune disease with the following exceptions:

    • Asthma and/or allergic rhinitis (seasonal allergies)
    • Vitiligo
    • Resolved childhood atopic dermatitis
    • Psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger.
    • Residual hypothyroidism due to an autoimmune condition only requiring hormone replacement
    • Euthyroid participants with a history of Grave's disease (participants with suspected autoimmune thyroid disorders must be negative for thyroglobulin and thyroid peroxidase antibodies and thyroid stimulating immunoglobulin (Ig) prior to the first dose of study treatment).
    • Type 1 diabetes mellitus
  • History of malignancy within the last 2 years (except non-melanoma skin cancers and superficial bladder cancer) and for which no additional therapy is required or anticipated to be required during the study period.
  • Uncontrolled major active infectious, cardiovascular, pulmonary, hematologic, or psychiatric illnesses that would make the patient a poor study candidate
  • Known prior or current history of HIV and/or hepatitis B/C
  • Prior organ allograft

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03689699


Locations
Layout table for location information
United States, New York
Weill Cornell Medical Center
New York, New York, United States, 10021
Columbia University Irving Medical Center
New York, New York, United States, 10032
United States, Pennsylvania
Sidney Kimmel Cancer Center- Thomas Jefferson University
Philadelphia, Pennsylvania, United States, 19107
Sponsors and Collaborators
Matthew Dallos
Bristol-Myers Squibb
Investigators
Layout table for investigator information
Principal Investigator: Matthew Dallos, MD Columbia University
Layout table for additonal information
Responsible Party: Matthew Dallos, Assistant Professor of Medicine, Columbia University
ClinicalTrials.gov Identifier: NCT03689699    
Other Study ID Numbers: AAAR7949
First Posted: September 28, 2018    Key Record Dates
Last Update Posted: May 11, 2022
Last Verified: May 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Matthew Dallos, Columbia University:
Immunotherapy
Nivolumab
BMS-986253
Degarelix
HuMax IL-8
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Prostatic Diseases
Nivolumab
Antineoplastic Agents, Immunological
Antineoplastic Agents
Immune Checkpoint Inhibitors
Molecular Mechanisms of Pharmacological Action